Avid Bioservices Inc (CDMO)

[Protector]

geocappy, absolutely correct.

I wonder thought what incentive AstraZeneca must have received or been promised for them to sponsor the Durvalumab knowing very well that each BP with a PD-1 or PD-L1 will benefit from the results from such trial because all in that category do exactly the SAME thing: keeping PD-L1 ligands from binding with PD-1 receptors.

Would they just count on the head start it gives them, assuming that the others would also have to start with a PI? Don't they fear an FDA regulation change for this NEW category of products where the FDA could allow to skip the PI is one in a same condition and type of main antibody (PD, CTLA, etc) has yielded good results?

They must have covered all that. Their management (from AZ) clearly show that they understand the game of being first, and its importance in sales and establishing new SOC heights.

They know if I-O+Bavi yields the results as seen in pre-clinical all BP's are going to be all over PPHM.